Anaptys Announces Participation in March Investor Conferences
Rhea-AI Summary
AnaptysBio (ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, has announced its participation in three major investor conferences in March 2025. The company's leadership, including President and CEO Daniel Faga, will attend:
- TD Cowen 45th Annual Healthcare Conference in Boston (March 4)
- Leerink Partners 2025 Global Healthcare Conference in Miami (March 11)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 12)
The events will feature fireside chats, presentations, and one-on-one investor meetings. Live webcasts will be available on the company's investor relations website, with replays accessible for 30 days post-events.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ANAB gained 2.56%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
TD Cowen 45th Annual Healthcare Conference, Boston, MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Mar. 4, 2025 at 1:10pm ET / 10:10am PT
Leerink Partners 2025 Global Healthcare Conference, Miami, FL
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Mar. 11, 2025 at 10:40am ET / 7:40am PT
Barclays 27th Annual Global Healthcare Conference, Miami, FL
- Format – Presentation and one-on-one investor meetings
- Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT
Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the TD Cowen Healthcare Conference 2025?
Where can investors watch AnaptysBio's (ANAB) March 2025 conference presentations?
Which investor conferences is AnaptysBio (ANAB) attending in March 2025?
What time is AnaptysBio's (ANAB) presentation at the Barclays Healthcare Conference 2025?
